Adherence to Clinical Practice Guidelines and Colorectal Cancer Survival: A Retrospective High-Resolution Population-Based Study in Spain
Metadatos
Afficher la notice complèteAuteur
Carrasco Peña, Francisco; Rodríguez Barranco, Miguel; Petrova, Dafina; Marcos Gragera, Rafael; Sánchez Pérez, María JoséEditorial
MDPI
Materia
Colorectal cancer Adherence Clinical practice guidelines Population-based study High-resolution study Cancer survival
Date
2020Referencia bibliográfica
Carrasco-Peña, Francisco; Bayo-Lozano, Eloisa; Rodríguez-Barranco, Miguel; Petrova, Dafina; Marcos-Gragera, Rafael; Carmona-Garcia, Maria C.; Borras, Josep M.; Sánchez, Maria-José. 2020. "Adherence to Clinical Practice Guidelines and Colorectal Cancer Survival: A Retrospective High-Resolution Population-Based Study in Spain." Int. J. Environ. Res. Public Health 17, no. 18: 6697. [DOI: 10.3390/ijerph17186697]
Patrocinador
ERANET within the framework of the call on "Translational research on tertiary prevention in cancer patients" (TRANSCAN); Instituto de Salud Carlos III AC14/00036; Andalusian Department of Health, Research, Development, and Innovation PI-0152/2017Résumé
Colorectal cancer (CRC) is the third most common cancer worldwide. Population-based,
high-resolution studies are essential for the continuous evaluation and updating of diagnosis
and treatment standards. This study aimed to assess adherence to clinical practice guidelines
and investigate its relationship with survival. We conducted a retrospective high-resolution
population-based study of 1050 incident CRC cases from the cancer registries of Granada and
Girona, with a 5-year follow-up. We recorded clinical, diagnostic, and treatment-related information
and assessed adherence to nine quality indicators of the relevant CRC guidelines. Overall adherence
(on at least 75% of the indicators) significantly reduced the excess risk of death (RER) = 0.35 [95%
confidence interval (CI) 0.28–0.45]. Analysis of the separate indicators showed that patients for whom
complementary imaging tests were requested had better survival, RER = 0.58 [95% CI 0.46–0.73], as
did patients with stage III colon cancer who underwent adjuvant chemotherapy, RER = 0.33, [95%
CI 0.16–0.70]. Adherence to clinical practice guidelines can reduce the excess risk of dying from
CRC by 65% [95% CI 55–72%]. Ordering complementary imagining tests that improve staging and
treatment choice for all CRC patients and adjuvant chemotherapy for stage III colon cancer patients
could be especially important. In contrast, controlled delays in starting some treatments appear not
to decrease survival.